Clinical trial · Observational
Long-Term Follow-up Study for Patients Previously Treated With JCAR015
Long-Term Follow-up Protocol for Subjects Treated With JCAR015
NCT02813252CI-TRIAL-00058898completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| JCAR015 | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- JCAR015-treated
- description
- Patients who received previous treatment with JCAR015
- interventionNames
- Genetic: JCAR015
Primary outcomes (4)
- measure
- Proportion of patients with adverse events
- timeFrame
- Every year for up to 15 years post-treatment
- measure
- Proportion of patients with detectable JCAR015 vector sequences during first 5 years post-treatment
- timeFrame
- Every 6 months for the first 5 years post-treatment
- measure
- Proportion of patients with detectable JCAR015 vector sequences between 5 and 15 years post-treatment
- timeFrame
- Every year from 5 years post-treatment to up to 15 years post-treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Patients who have received at least one dose of JCAR015 in a previous treatment protocol. * Patients who have provided informed consent for the long-term follow-up study prior to study participation. Exclusion criteria: * None. All patients who have previously received JCAR015 treatment are eligible for this long-term follow-up study.
References
Publications (0)
Data not yet available
No reference posted for this study.